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1 Biological Background 
 
1.1 Biology of the Dopamine Transporter 
 
1.1.1 Dopamine 
 
Dopamine is a neurotransmitter belonging to the monoamine family. It is biosynthesized in 
various locations of the nervous system in two steps (Figure 1) out of the amino acid Tyrosine 
and furthermore it is also the precursor for Epinephrine and Norepinephrine.   
 
 
 
 
On the one hand Dopamine has several functions in the periphery but also in the central 
nervous system. Two groups containing five subtypes of dopamine receptors (D1-D5) are known.  
In the periphery it is involved in the regulation of the blood pressure and kidney blood flow. The 
effects in the CNS are diverse. It plays an important role in regulating the lactation (via 
prolactin), the motor function and several affective and cognitive processes. Therefore many 
diseases (for example M. Parkinson and schizophrenia) are associated with the malregulation of 
dopamine concentration in some parts of the human brain. (Steinhilber et al. 2005) 
 
 
Figure 1 
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1.1.2 The Dopamine Transporter 
 
The dopamine transporter (DAT) has the function to pump dopamine out of the synaptic cleft 
into the neuron after its release. It is a transmembrane protein consisting of 12 α-Helices and 
one bigger extracellular loop. The N- and the C-terminus both face the inside of the cell (Figure 
2). Until today no crystal structure has been obtained and therefore the exact 3D structure is 
still unknown. (Vaughan et al. 2005) 
 
 
 
 
 
 
 
Figure 2 taken from (Volz and Schenk 2005) 
DAT is a member of the sodium/monoamine neuro-
transmitter co-transporter family (other members: The 
serotonin transporter (SERT) and the norepinephrine 
transporter (NET)). Dopamine transport is driven by a Na+ 
gradient inwards the cell which is maintained by the 
membrane Na+/K+-ATPase. One molecule of dopamine is 
accompanied by two Na+ and one Cl- Ions. 
Many drugs interact with the monoamine transporters 
targeting them with different binding affinities. Some of 
Figure 3 taken from (Torres et al. 2003) 
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them like cocaine and methylphenidate block (Figure 3) the transporter which results in a higher 
concentration of the transmitters in the synaptic cleft. Amphetamine is even able to invert the 
direction of the dopamine transport (besides it also increases the neuronal excretion of 
dopamine vesicles). (Torres et al. 2003) 
 
1.1.3 Important interacting Drugs 
 
 Cocaine 
 
 
The coca plant Erythroxylum coca, which is native in South America, has been known for its 
stimulant hunger-suppressant effects for centuries. The drug is applied by chewing the 
leaves of the plant and people still use it this way today.(Goldstein et al. 2009) 
In the 19th century cocaine was extracted as an active substance and the drug was first 
widely used as an anesthetic drug (This effect is related to the block of sensory nerve fibers 
by blocking Na+Channels). But it wasn’t only used in the medical field: the leaves were even 
used for the preparation of alcoholic and non alcoholic beverages (the best known 
example is coca cola)(Goldstein et al. 2009). 
Today cocaine is one of the heaviest abused drugs even starting with adolescence.  
“The National Institute on Drug Abuse (NIDA)- funded 2007 Monitoring the Future Study 
showed that 2.0% of 8th graders, 3.4% of 10th graders, and 5.2% of 12th graders had 
abused cocaine in any form and 1.3% of 8th graders, 1.3% of 10th graders, and 1.9% of 
12th graders had abused crack at least once in the year prior to being surveyed.”    
  (Goldstein et al. 2009) 
Besides being one of the drugs with the highest addictive potential (Nutt et al. 2007) it can 
also cause severe side effects especially concerning the cardiovascular and the CN system. 
Due to its effects on the vascular system it increases the risk of a stroke or heart attacks 
Figure 4 
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and arrhythmia (Qureshi et al. 2001).   The psychic disorders caused by sustained cocaine 
abuse are wide ranging. 
As already mentioned before the stimulant effects of cocaine are the result of the 
unselective blockade of the three monoamine transporters DAT, SERT and NET.  
 
 
 
 Methylphenidate 
 
 
Methylphenidate (Figure 5) is an artificial drug which was first synthesized in the early 
1940s. It appeared on the market in the middle of the 1950s in the USA and Germany. At 
the end of that decade it was used for the treatment of “behavioral problems” in children 
for the first time. (Schmutz 2004) 
Today Methylphenidate is one of the most commonly used medicinal drugs to treat ADHD 
(Attention Deficit Hyperactivity Disorder) especially in children (Kollins et al. 2001). 
Furthermore it has also been under discussion as a substitution therapy for cocaine or 
amphetamine addicts. Until now no significant positive effects have been shown for 
cocaine dependence but there have been first positive outcomes regarding the treatment 
of amphetamine and met-amphetamine addicts. Nevertheless both indications need 
further investigation. (Grabowski et al. 1997; Elkashef et al. 2008; Konstenius et al. 2009)  
Like cocaine methylphenidate has a high affinity for blocking DAT and the NET while the 
affinity for SERT is significantly decreased. (Threo) Dexmethylphenidate HCl was identified 
as the more active one but until now also the racemate has still been in use. (Gatley et al. 
1996) 
Due to the rather similar type of pharmacokinetic and its stimulant effects it is no surprise 
that methylphenidate is also a drug that is abused. In therapeutic doses used for the 
Figure 5 (Threo MP) 
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treatment of ADHD its abusive potential is rather low.  However, this risk shouldn’t be 
disregarded. (Kollins et al. 2001) 
Methylphenidate can also cause a number of side effects: Tachycardia, headache, appetite 
loss, increase of blood pressure, allergic reaction and others have been 
reported.(Mutschler et al. 2008) 
 
 
 
 Amphetamin 
 
 
 
Amphetamine (Figure 6) first came up in the late 90s of the 19th century. It was synthesized in 
Germany at the ‘Berliner Humboldt-University’ during a dissertation. It took almost 50 years 
until the stimulating properties of the compound were brought to light and documented by 
Gordon Alles and the rest of his group.(Fleckenstein et al. 2007; Tauss 2008) 
Since then Amphetamine and its derivatives have been used for the treatment of many 
different diseases, including narcolepsy, ADHD and obesity (Seiden et al. 1993). But the 
treatment of illnesses wasn’t the only purpose the drug has been used for. Not only during the 
Second World War it was used to ‘improve the performance’ of soldiers during the fight (Tauss 
2008). Lately it was proposed in a Nature article that the use of amphetamines could be a 
benefit in a university environment to enhance the cognitive abilities of the users:  
“Based on our considerations, we call for a presumption that mentally competent adults 
should be able to engage in cognitive enhancement using drugs.”(Greely et al. 2008) 
Last but not least this substance family is like cocaine one of the most widely abused drugs. 
(Tauss 2008) Besides the high risk of dependence amphetamines can also cause many side 
Figure 6 
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effects. They are mostly congruent with the ones which were already mentioned in the 
methylphenidate section. (Mutschler et al. 2008) 
 
If you look at the molecules (Figure 6) you can see easily that methylphenidate and 
amphetamine are quite closely related according to their structure. Interestingly, the 
mechanism of action is not the same. Methylphenidate like cocaine blocks the dopamine 
transporter. This is not the case with amphetamine. Anyway the effect is the same: the 
concentration of dopamine in the synaptic cleft increases significantly. There are different 
hypotheses for its mechanism of action. Studies suggest that the compound is transported 
actively into the cell by the DAT just like dopamine itself. There it inverts the direction of 
transport and the transporter pumps dopamine out of the neuron. Another hypothesis 
indicates that amphetamine boosts the excretion of dopamine vesicles. Most likely more than 
one mechanism plays a role. (Pifl et al. 1995; Fleckenstein et al. 2007) 
Amphetamine also has a positive effect on the release of serotonin and noradrenalin (via NET 
and SERT). The quantity of released serotonin is much lower than that of the other 
neurotransmitters (Rothman and Baumann 2002).  
 
 Amphetamine derivatives  
 
One of the most prominent derivatives of amphetamine is MDMA (3,4- MethylenDioxy-N-
MethylAmphetamin) which was already synthesized in the early 20th century. It became very 
popular in the 1980’s and 90’s under the name Ecstasy, an illicit ‘club drug’ (Benzenhofer and 
Passie 2006; Senn et al. 2007). However, you can also find other amphetamine derivatives and 
other stimulating drugs in ecstasy tablets. Consumers can never be sure which - or how much - 
active substance is included (Parrott 2004). 
In contrast to amphetamine MDMA is about tenfold more active at SERT and NET than at DAT 
transporters (Rothman and Baumann 2002). It was the first member of a new group of drugs: 
Figure 7 MDMA 
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the entactogens. MDMA has not only stimulating but also hallucinogenic attributes which 
differentiates this family from the classical amphetamines.  
 
1.1.4 Attention Deficit Hyperactivity Disorder (ADHD) 
 
As ADHD is currently a very important indication for methylphenidate (and also for 
amphetamine) a few facts about the disease should be given.  
Normally the disorder arises in children before the age of six. Persons with ADHD are not able 
to keep up attention and focus on something. They are easily detracted and because of their 
permanent agitation these people are often referred to as ‘Fidgety Philip’. It’s hard for them to 
plan their activities and think foresightedly. By definition you only speak of ADHD when the 
symptoms show over a period longer than 6 months and occur in at least two different areas of 
life (for example at school and at home with family). Also the disease is quite often 
accompanied by other psychic syndromes like depression or anxiety disorders. 
In general the therapy is very important. When the disease is not treated children can easily 
have deficits in their social and intellectual development. Different factors are important for a 
successful therapy. First, it is very important to make the child’s environment aware of the 
circumstances and also give them further advice how to interact with the kid. Secondly the 
patient should undergo psychotherapy. Finally, this can also be combined with 
pharmacotherapy. (Gerlach et al. 2009) 
For the medicinal treatment methylphenidate and amphetamine are the first choice. 
Methylphenidate is favored as long as the effect is strong enough. If that is not the case 
amphetamine is used. Both drugs are well capable of reducing the symptoms of ADHD. In the 
last years retarded versions of the drug were more often used. They show the benefit of better 
patient’s compliance. (Gerlach et al. 2009) 
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Other drugs used for the treatment: Atomoxetin can be considered as second choice (only for 
special indications as a first choice) and other stimulants and antidepressant drugs as third 
choice. (Gerlach et al. 2009)  
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2 Computational Background 
 
There are different ways to analyze interactions between a compound and a biological target 
(protein). You can separate them into two larger groups: Ligand and target based methods. 
 
2.1  Ligand based Methods: Quantitative Structure Activity Relationship 
 
2.1.1 Theory: 
 
The idea of QSAR is it to differences in the chemical structure with differences in the 
activity/affinity of a compound. This can be used for different purposes, on the one hand for in 
silico virtual screening of large databases of compounds to make predictions which of them 
could be interesting for further testing. Hereby one can save money and time. On the other 
hand you can use the results of a QSAR analysis to see which substructures and chemical 
properties of a compound could be of importance for the interaction with the target and which 
of them are weakening it. The big advantage of this computational method is that you do not 
need to know the structure of the target to make certain assumptions about the interaction 
pattern. But even if you do know the structure the combination of structure- and ligand-based 
methods can be beneficial. (Klebe 2009) 
 
2.1.2 Requirements: 
 
Compounds can only be compared by a QSAR analysis if they are chemically quite similar and of 
course it’s only possible to compare substances in regard to their affinity if they all interact with 
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the same target. It is necessary to have a series of compounds with experimentally determined 
affinity data for the target protein.  
 
2.1.3 Descriptors: 
 
In order to be able to compare molecules you need to be able to describe their chemical 
properties. A QSAR model is a purely mathematical model, so you need to convert chemical 
features into numeric values. This is what descriptors do: they define certain chemical features 
numerically and thus make them quantifiable. 
“The molecular descriptor is the final result of a logical and mathematical procedure which 
transforms chemical information encoded within a symbolic representation of a molecule into a 
useful number or the result of some standardized experiment.” (Todeschini and Consonni 2000) 
 
A few examples:   
 
 
 
 
 
 
Descriptors can be calculated quite rapidly. The calculation of a small number of descriptors is 
based on experimental determined data, but most of them are calculated right away if the 
molecule is given (for example the number of atoms). 
 
logP (o/w):  Logarithmic partition coefficient octanol/water 
weight: Molecular weight of a molecule 
a_acc:   Number of H-bond acceptors in the molecule 
Pc+:   Total positive partial charge 
 
(Chemical Computing Group 2009) 
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2.1.4 Hansch-Analysis: 
 
In 1964 Hansch and Fujita developed the so called “Hansch-Analysis”. This was the first real 
“QSAR Equation”.  It is a multiple linear regression model which gives an equation as folows: 
 
 
 
This equation is normally accompanied by the following statistical terms: 
 
 
 
 
“Log1/C” is the logarithmized reciprocal of the calculated activity (The EC50 or IC50 value). 
“DesX” is a certain descriptor and “kx” is the regression coefficient which shows the amount of 
contribution to the model of each descriptor. 
 
2.1.5 HQSAR: 
 
1. The Method 
HQSAR is a fragment based QSAR method available in the Sybyl software package by 
(TriposTMInc. 2007). It correlates features of substructures of a molecule with biological activity. 
It is a fast and easily applicable method which only requires 2D structures as input format and 
the activity data of these molecules. In contrast to normal 3D QSAR no alignment is necessary.  
 The analysis consists of two steps: 
1. Creation of the molecular holograms 
“n” is the number of compounds 
“R” is the correlation coefficient  
“S” is the standard deviation of the model 
 
Log 1/C =  k1*(DesA) + k2*(DesB) - k3*(DesC)… 
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2. Correlation of the hologram with the biological activity via PLS 
 
2. Details 
 
First, molecules are 
divided into all 
possible fragments 
(of connected atoms) 
of a certain length. 
Subsequently they 
are transformed into 
molecular holograms, 
strings of integers,  
via two different 
algorithms (Figure 8). 
(Lowis 1997)  
 
The hologram encodes all unique fragments, also branched and cyclic and overlapping ones.  
The fragment and the hologram length can both be set by the user which affects the quality of 
the model. 
The user can choose six different features which define the fragment as unique. These featured 
are listed as follows: 
 
1. Atom:   Based on the element types  
2. Bond:    Based on the bond types 
3. Connection:  Based on the hybridization state 
4. Hydrogen:  Hydrogen Atoms are included or not 
Figure 8 taken from (Lowis 1997) 
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5. Chirality:  Based on chirality 
6. Donor & Acceptor: Searches for predefined donor or acceptor atoms 
 
Stereochemistry can be considered as well. By taking these features into account one can see 
that 3D structural information is included to a certain extent, which differentiates the method 
from 2D QSAR analyses.  (TriposTMInc. 2007) 
The holograms of the different fragments are then correlated to the given activity data via PLS 
(Partial Least Squares)  
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2.2 Structure based Methods: Small ligand docking 
 
Small ligand docking is a method used in structure based drug design. The idea of structure 
based design first came up in the early 1970s in London in the group of Chris Bedell and Peter 
Goodford. They tried to investigate new agents for the DPG (Bisphosphoglycerate) binding site 
of Hemoglobin, which at that time was the only known protein structure known to be 
responsible for a disease, namely the Sickle-cell disease.(Klebe 2009) Though the methods and 
the possibilities have changed greatly since that time, their work laid the cornerstone for 
structure based in silico methods.  
One of today’s aims of small ligand docking is to deduce predictions from the properties of the 
protein surface concerning the interaction mode of a ligand with the target structure.  Basically 
in SLD a small molecule is positioned in the binding pocket via a placement method and after 
that the docking program calculates if the interactions are energetically preferred or not. These 
calculations are done by a scoring algorithm which uses different energy terms. The given score 
makes the single ligand poses comparable and analyzable. Another application area for docking 
is the screening of ligand databases versus one target protein. As the screening approach was 
not used in this work it will not be described in further detail.  
It is mandatory for a docking process that some facts are known about the target’s structure.  
The characteristics of the protein have to be studied in detail before a docking job can be 
started. You need a 3D conformation for analysis. In the optimal case the protein structure is 
known from X-ray diffraction measurements. These can depict the exact structure of the 
protein in a certain conformation. Often this is not possible as there are no X-Ray structures 
available. There are alternatives to creating a model structure from closely related protein 
families via alignment and further processing. These models are called homology models. 
If the interacting partner amino acids for the ligand in the receptor have been 
uncovered, one can try to make predictions for the effect of structural modifications of the 
ligand. One can try to increase the affinity of the ligand or just design optimal ligands for this 
binding site. This is called rational structure based design.(Klebe 2009) 
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2.3 Aim of the Work 
 
The detailed mechanism of interaction of methylphenidate in the dopamine transporter is still 
unknown. Although many structural derivatives of the compound were tested in terms of 
affinity to the dopamine transporter no residues of the protein have been investigated to be 
crucial for this interaction. 
It was the aim of this work to investigate the binding mode of methylphenidate in the 
transporter. 
To achieve this, as a first step, a set of methylphenidate derivatives will be analyzed in QSAR 
experiments. The developed QSAR models should not only be useful tools for the prediction of 
ligand affinity. Here these models should additionally be used for interpretational purposes. 
It will be checked if structural influences on DAT affinity values - observed in the ligand based 
analyses - can be explained by interactions proposed in structure based models which will be 
created as a second step. This will be done in docking experiments in a homology model of the 
Dopamine transporter with flexible side chains. 
By this combination of structure and ligand based methods the inevitable uncertainties which 
are associated with a docking experiment using a homology model as a protein structure, 
should be compensated to obtain a reliable methylphenidate binding pose in the Dopamine 
transporter. 
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3 Methods 
3.1 Creation of a Ligand Database 
 
First a database of the methylphenidate derivatives with available affinity data for the 
dopamine transporter was created. This was done by an intensive screening of the literature, 
which resulted in a final dataset of 135 derivatives in total. Some of the recorded compounds 
only differ stericly: the threo or erythro form or different enantiomers. The database was 
generated in the MOE Package using the builder tool to create the chemical structures. 
 
Each entry got a name which makes it possible to trace its origin back to the appropriate study. 
Example: P A2 RR 10h 
The first three characters indicate the source of the compound. “P” stands for Paper/Study and 
A1-A7 is an internal numbering. The following letters are the designation of the compound used 
in the study. 
The list of the sources for the database: 
P A1 (Schweri et al. 2002) 
P A2 (Froimowitz et al. 2007) 
P A3  (Davies et al. 2004) 
P A4 (Meltzer et al. 2003) 
P A5 (Kim et al. 2007) 
P A6 (Gatley et al. 1996) 
P A7 (Deutsch et al. 1996) 
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3.2 Creation of 2D-QSAR and H-QSAR Models 
 
3.2.1 2D-QSAR Model with broad structural range 
 
First of all the dataset had to be adjusted to the needs of a 2D-QSAR analysis. As  enantiomers 
cannot be differentiated when 2D descriptors are used, only one enantiomer of each 
compound including its activity data was kept in the database. Furthermore, the data of threo-
diastereomer was preferred to that of the erythro-diastereomer, since the former are 
described as the active ones in literature (Gatley et al. 1996), which is quite obvious when you 
look at the activity data of these compounds.  
The given dataset was divided into a test and a training set before the creation of the QSAR 
Model. 20% of the compounds where selected via the MOE tool “Diverse Subset”. This feature 
ranks the compounds according to their distance to each other in diversity metric. (Chemical 
Computing Group 2009) So the most diverse agents were selected automatically for the test 
set. The remaining 80% of the dataset were used to create a training set. 76 methylphenidate 
derivatives formed the training set and 18 the test set.  
Descriptors which describe basic molecular properties where calculated using MOE.  Examples 
of the descriptors used: Number of Rotatable Bonds, Molecular Weight, Molrefraction, Number 
of Hydrogen Bond Acceptors/Donors, ClogP(o/w)  and others. 
In a second run a series of VSA descriptors 
were used for the creation of the model. In 
addition to that an Auto QSAR Script, which 
evaluated different descriptor combinations 
automatically via PLS analyses, was used. 
These automatically created models are not 
perfect, but they do give you a clear hint to 
some descriptors which could be useful for 
Figure 9 Poor correlation using global 2D-QSAR models 
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the model of the correspondent series of compounds. Nevertheless, even with extensive 
optimization of the model no optimal equation could be obtained. The final model was applied 
to the test set. As can be seen in the correlation plot on the left side (Figure 9) the correlation of 
the predicted values with the actual ones is not very high. 
As it was not possible to create a predictive model for the whole derivative dataset the number 
of the included compounds was reduced. 
 
3.2.2 2D-QSAR Models with smaller structural range  
 
 Selected studies were investigated individually to have a smaller range of structural diversity. 
So the influence of small structural changes on the biological activity could be analyzed in 
detail. 
In consideration for the size of the datasets it was decided to validate the models via leave one 
out cross validation, as the size of a test or training set would not have been big enough and so 
not very significant for testing the model. 
Model 1: 
First compounds of study A7 (Deutsch et al. 1996) were used to 
determine how different substituents at various positions of the 
methylphenidates phenyl ring (Figure 10) affect the affinity.  
 
For this QSAR analysis not only descriptors calculated in MOE were used for the equation but 
also Sigma Hammett, Pi , Es and MR constants from “Substituent Constants for Correlation 
Analysis in Chemistry and Biology”(Hansch 1979). 
The Model was created on basis of 24 compounds from study A7 which are listed in section (G
 Compounds used for the QSAR Models) 
 
Figure 10 
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Model 2: 
Compounds of study A2 were analyzed next. In these compounds 
methylphenidate’s carboxy methyl ester group is replaced by different 
more lipophilic alkyl groups. The compounds differ in size and length of 
these alkyl groups (Figure 11: R1).  
 
The descriptors used in this model all were calculated within the MOE Software Package. 
 
The 25 Compounds used for the creation of the model are listed in section (G Compounds 
used for the QSAR Models) 
 
3.2.3 Creation of the H-QSAR models: 
 
To reinforce the models also H-QSAR analyses of these datasets were accomplished with the 
Sybyl 8.0 Software Package (TriposTMInc. 2007). 
Around 40 primary models were created for each final model using different combinations of 2 
to 4 of the 6 available H-QSAR descriptors (Atom, Bond, Connection, Hydrogen, Chirality ,Donor 
& Acceptor) and the default fragment size of 4-7 atoms. The results were validated via leave 
one out cross validation. The one with the highest cross validated R2 value was chosen to be 
processed further. After that, different models were calculated with the determined 
descriptors, only the fragment size was systematically changed.  Again the optimal one was 
chosen. This is the final model. The aim was to gain activity predictions with residual values 
below one order of magnitude. 
 
 
Figure 11 
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Combination of successful H-QSAR models 
 
As a last step to verify whether it is possible to create reasonable H-QSAR Models via 
compounds with a broader structural diversity range, two additional models were created. One 
included the compounds of study A2 and A7 and one included the ones of study A2, A5 and A7. 
 
Compounds study A5:  
The compounds analyzed in this study were more diverse than the ones of 
the other two studies. Anyway it focuses on restricted rotation analogues 
with a substituted scaffold as it is shown in (Figure 12). 
 
The detailed development of the QSAR models as well as the outcome of these analyses are 
described in the result section. 
 
 
 
 
  
Figure 12 
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3.3 Docking Basis and Workflow 
 
3.3.1 The Dopamine transporter model 
 
Since currently no crystallographic structure of the Dopamine transporter, determinated by X-
Ray diffraction, is available, a homology model had to be created. The model of (Weissensteiner 
2008) was used. This model was created on basis of the high resolution (2Å) crystallographic 
structure of the LeuT of “Aquifex Aeolicus” published by (Singh et al. 2008) (PDB: 3F3A). The X-
Ray structure shows the protein in an open to out conformation state. The bacterial Leucine-
Transporter is an established model for the mammalian Neurotransmitter-Na+-Symporters 
transporter family structurally matching with the Dopamine Transporter. (Weissensteiner 2008) 
 
3.3.2 The Binding Sites 
 
Up to now no binding sites for Methylphenidate in the Dopamine Transporter have been 
published. Nevertheless, there are two prominent and recent poses for cocaine in the DAT, 
published by the group of Beuming (Beuming et al. 2008) and one by the group of Huang 
(Huang et al. 2009), which are depicted in Figure 13. Due to the similar type of interaction of 
Cocaine and Methylphenidate at the transporter, as already mentioned in the “Biological 
background” section, the proposed cocaine binding modes where taken as a clue for a possible 
binding pocket for Methylphenidate. While the binding site proposed by the group of Beuming 
overlaps with that of Dopamine and Amphetamine (Beuming et al. 2008) the initial one of 
Huang’s group is close to the Dopamine site but does not overlap.(Huang et al. 2009) Huang 
further states that a later move of cocaine to the Dopamine binding site after a conformational 
change of the transporter protein, resulting in an expansion of the binding pocket, is possible.  
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Yellow: Beuming’s binding site 
White:  Huang’s binding site 
Red:  overlapping of the two 
proposed sites 
 
Figure 13 
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Due to extensive experimental validation of the computational model of (Beuming et al. 2008) 
this suggested binding pocket was preferred over the other one. The model was not only 
validated in mutagenesis experiments but the authors also trapped the radio labeled cocaine 
analogue [H3]-CFT in the binding site over cysteine cross linking. 
The following amino acids were identified to form the cocaine pocket: 
 
 
3.3.3 The Compounds 
 
Five highly potent Methylphenidate analogues and Methylphenidate itself were chosen for the 
docking runs, four alkyl and one ester derivative analogue. (Figure 14)  
 
  
PHE76 ASP79 SER149 VAL152 TYR156 Phe320 PHE326 VAL328 SER422 ALA423 GLY425 
Figure 14 
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Though only the affinity data for the Threo-racemates (d/l) of these methylphenidate 
derivatives are available in literature you have to choose a distinct steric conformation of the 
molecules for the program to work with. As the d-threo form of methylphenidate is described 
as the more active inhibitor (Gatley et al. 1996) this form was chosen for the docking runs. 
 
3.3.4 Docking with GOLD 
 
The Gold Suite 4.1.1 (Hermes) for Microsoft Windows© was the first program used for the 
docking experiments. To validate if the program and the method were suited for the following 
docking experiments a redocking was performed: 
The crystal structure complex (3F3A) of LeuT and L-Tryptophan was used for the validation. 
As one can see in Table 2 among the first twenty top scored poses 18 are within an RMSD of 
under 0.5 Å to the reference ligand, which is a good value. So the system was considered to be 
suited for the following docking experiments. 
Nevertheless, Numbers 19 and 20 of the score show that trusting in scoring functions alone is 
not recommendable. Good scores do not always correlate with right docking poses and so 
other aspects should be taken into consideration as well when different poses or clusters are 
evaluated. 
Index Gold Score RMSD  Index Gold Score RMSD 
1 48.508 0.330  11 47.604 0.345 
2 48.327 0.351  12 47.585 0.446 
3 48.327 0.413  13 47.495 0.284 
4 48.234 0.440  14 47.446 0.338 
5 48.227 0.475  15 47.395 0.464 
6 48.216 0.315  16 47.259 0.392 
7 48.021 0.405  17 47.040 0.342 
8 47.931 0.341  18 47.005 0.371 
9 47.705 0.330  19 46.206 5.023 
10 47.621 0.383  20 45.201 5.056 
Figure 15 
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3.3.5 Final Workflow: Docking with flexible sidechains in GOLD 
 
1. First the protonated methylphenidate derivatives were 
docked into the protein. 
Settings:  
First the protein was prepared in GOLD Setup. Hydrogens were 
added and water molecules deleted. The docking site was 
defined by a text file, listing the already suggested amino acids. 
The side chains were set to be flexible via the creation of 
different rotamers. The program created the rotamers using a 
library. 
The number of poses was set to 150 for each of the six 
compounds to cover a wide range of possible positioning. 
Furthermore the possibility of early docking determination was 
cancelled to receive a maximum of poses. 
The ligand-input-file (an sdf database file) and also an output file 
were defined.  Then the docking run started. 
After the docking run was finished the poses had to be 
evaluated. The following steps are done in MOE. 
 
2. The data had to be exported and processed so they could 
be used and interpreted in the Molecular Operating 
Environment software, which is not a trivial task. 
 
The ligand-protein complexes had to be exported from the GOLD output sd file to an mdb file. 
While the positioning and the coordinates of the ligands were saved in a molecule database 
field, the structural changes of the DAT protein resulting from the flexibility  
DOCKING IN GOLD
EXPORT TO MOE
PROCESSING 
COMPLEXES
REFINEMENT→LIGX
RMSD CLUSTERING
CLUSTER SELECTION
POSE EVALUATION
Figure 16 
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of the side chains were written to a coordinate matrix (Figure 17) by GOLD. The program used 
them in combination with the primal Protein input file to depict the new altered proteins. MOE 
cannot interpret the coordinate matrices by itself.  
However, a Python script (“apply_rotated_atoms.py”) is provided with the GOLD Suite package 
(CCDC 2009) to apply these matrices to the protein model. This script exports the new 
conformations into mol2 files, one file per ligand. All these mol2 files had to be transferred to 
an sdf-database file. Afterwards, the protein field has to be combined with the correspondent 
ligand field for the interpretation process. 
 
 
 
 
  
Figure 17 
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3. Processing the Complexes 
 
As GOLD uses different methods to calculate receptor ligand interaction, lone pairs, which are 
created by the GOLD during the docking process, had to be deleted and charges had to be 
recalculated. This was done via the function “Protonate 3D” in MOE. This function does not 
only add hydrogen atoms but also calculates ionization states and partial charges. The 
calculations are based on user settings, defining the protein environment with different 
parameters like temperature, pH, salt concentration and the dielectric constant. Standard 
settings have been used. 
 
 
4. Minimization of the Complexes 
 
LigX, a program implemented in MOE, offers a function to minimize the pocket and the ligand 
using a forcefield. 
The three steps of deleting the lone pairs the protonation step, and the complex minimization 
were scripted to speed up the process. 
 
5. Clustering of the poses 
 
The poses were clustered according to the 
RMSD of their maximum common 
substructure. 
To do this, first the molecules have to be 
divided into fragments. The maximum 
common substructure has to be defined by 
the user. Then the MSC is copied to a new Figure 18 
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mol field for each ligand maintaining the positional information. This new database field is used 
by the clustering script during the process. 
Then the poses are clustered hierarchically. A threshold can be set by the user, specifying the 
maximum RMSD deviation for the poses within one cluster. All poses that exceed this limit are 
assigned to different clusters. 
 
 
 
 
 
 
 
 
 
 
 
 
6. Cluster selection 
 
The given pose clusters had to be evaluated and their number had to be limited down to make 
them interpretable and to find the correct one. As a first criterion, only clusters were 
considered which contained poses of each of the six compounds. All docked ligands belong to 
the same structural class and have high affinity to the transporter. Therefore one can assume 
that they interact with the protein in the same manner. 
There are different possibilities to weight the remaining clusters. This can either be done 
computationally using scoring functions, by the size of the cluster, or experimentally by 
comparing the protein-ligand interaction fingerprint (PLIF) with mutational data. 
 
 
Figure 19 
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Steps until the final workflow was obtained 
Three docking runs were performed with GOLD 4.1.1 before the optimal workflow was 
obtained.  
 
First run: 
Unprotonated ligands were used for the first docking run. The output number was set to 20 
poses per ligand (120 poses in total). The protein itself was rigid. No minimization was applied 
after docking. The poses were clustered according to their common scaffold with a threshold of 
1.9 Å. This resulted in five different clusters. 
Cluster number five was by far the biggest one, containing 63 of the 120 poses and five of the 
six docked compounds. 
 
Figure 20 
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 In this model only protein-ligand interactions with 
the nitrogen atom of the methylphenidate 
derivative could be observed. The PLIF (Figure 20) 
shows the amino acids which interact with this 
basic group. Asp 79, which is also described as the 
essential interaction partner for the amino group in 
cocaine (Beuming et al. 2008), is an important 
interaction partner for the amine nitrogen of 
methylphenidate and its derivatives, other 
significant interaction partners are Phe320 and 
Ser422. The pose of methylphenidate itself differs a 
little from the other compounds in this cluster 
(Figure 21 in red). That was also the reason why it is 
the main interaction partner of Ser422 in this cluster. 
The cluster did not only include the highest number of poses and compounds, it also contained 
the poses which were ranked best with the GOLD score. 
 
   
 
 
 
 
 
 
The GOLD score is calculated considering four elements: 
 Energy of hydrogen bonds between receptor and ligand 
 Van der Waals energy of receptor and ligand 
 Internal vdw energy of the ligand  
 Energy of Torsional strain of the ligand 
 
The score value arises out of the negative value of the sum of 
the individual energy terms  the larger the fitness score the 
better the positioning. (CCDC 2010) 
“GOLD Fitness = Shb_ext + Svdw_ext + Shb_int + Svdw_int” 
(Marcel et al. 2003) 
 
Figure 21 
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However, the cluster did not contain any pose of the compound “P A2 RR 
10c” (Figure 22).  As the number of poses per ligand was rather small, 
namely 20 poses, this was considered to be one possible reason for the 
absence of this compound.  
 
Second run: 
To find a cluster which contains all six compounds the pose number per compound was 
increased to a hundred. Other parameters weren’t altered in this second run. 
Clustering the compounds led to eight different clusters (1.7 Å RMSD deviation). One of them 
contained poses of all six compounds and was analyzed further.  
 
 
Figure 23 
The PLIF of the Cluster (Figure 23) shows rather similar interaction compared to the first 
docking run with Asp79 and Phe320 interacting with the amino group of the ligands. 
Interestingly, nearly no interaction is observed with Ser422. This can be explained with the 
difference of the methylphenidate pose,  as the former Methylphenidate’s pose was the main 
Figure 22 
Comp “P A2 RR 10c” 
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interaction partner for Ser422 in the GOLD docking run number 2 (see Page 39 Figure 21).  In 
contrast to the last run the threshold was lowered from 1.9 to 1.7Å RMSD deviation. So the 
other pose of methylphenidate - seen in Figure 21 - was assigned to another cluster. Now the 
position of the methylphenidate poses overlapped with those of the derivatives.  
3.1.4 Docking with MOE 
 
This docking run in the molecular operating environment suite was accomplished to compare 
its poses with the docking results which were received with the GOLD suite. If these concurred 
with each other it would be useful for the reinforcement of the GOLD poses and also help to 
choose the preferred one. As it was mainly of interest if the same poses could be found, MOE’s 
standard docking settings were used without an extensive check of all available placement 
scoring functions. 
The detailed settings and the results are described in detail in the result section “4.2.2
 Docking with MOE”. 
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4 Results 
 
4.1 QSAR – Ligand based methods  
 
4.1.1  2D-QSAR Model phenyl ring substituted analogues 
(A7) 
 
As already mentioned in the method section the 24 compounds used for the creation of this 
model mainly differ in the substitution of the aromatic ring system. The three positions shown 
in Figure 24 are occupied by various residues: In most of the cases halogens (Cl,Br,J,F), hydroxyl- 
or methoxy groups are attached to one or two of them.  There are also compounds with an 
amine- a nitro- and a tert.But rest attached. 
Two kinds of descriptors were used for the creation: on the one hand global ones which 
described the whole molecule and on the other hand substitution constants only describing the 
contribution of the single substituents to the activity. 
 
Step 1: The descriptive substituent constants (Hansch 1979) Pi Ortho, Pi 
Meta, Pi Para, Sigma Ortho, Sigma Meta, Sigma Para, MR Ortho, 
MR Meta, MR Para, Es Ortho, Es Meta, Es Para were used. 
 
Figure 25: Correlation predicted/actual Step 1  
RMSE: 0.44515 
R2:  0.85876 
XRMSE: 2.10569 
XR2:  0.17379 
Nr. C. 12 
Figure 24 
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 Step 2: After an analysis of the outliers of Step 1 the parameter vdw_vol 
was calculated and added to describe the influence of 
substituents’ size (e.g. tert. Butyl and -NO2  The compounds in 
Figure 25: Correlation predicted/actual Step 1 marked with 
white rings) at the aromatic ring systems more accurately which increased predictivity. 
The equation could describe two additional compounds only poorly: The ones marked 
in with red rings. One of them was hydroxylated in Ortho- and one methylated in 
Meta- position. 
 
 
Figure 26 Rel. Importance of Descriptors Step 2 
 
Step 3: 3 statistically unimportant descriptors were excluded via 
backward selection: Sigma meta, Sigma para and Es meta. The 
dimensionality was reduced via PLS to 9 components. 
  
 
 
 
0.92
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0.04 0.03
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0.27
0.41
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0.60
0
0.2
0.4
0.6
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1
Rel. Importance of Descriptors Step 2
RMSE: 0.25409 
R2:  0.95398 
XRMSE: 1.06742 
XR2:  0.50378 
Nr. C. 13 
RMSE: 0.32619 
R2:  0.92416 
XRMSE: 0.99356 
XR2:  0.54418 
Nr. C. 9 
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Step 4: An automatic QSAR script was used to find other descriptors 
that could contribute to the model positively. Due to this 
analysis the Weiner Path Descriptor was added. The Component 
limit was set to 9. 
 
 
 
Figure 27  Rel. Importance of Descriptors Step 4 
 
Step 5: Again 2 descriptors were excluded because of their insignificance for 
the model. Pi para and Es para. The Component Limit was set to 7. 
 
 
 
Step 6: A correlation matrix analysis (Figure 28) for the descriptors was 
performed to identify redundant descriptors. Sigma ortho highly 
correlated with Pi ortho and Es ortho with MR ortho. MR ortho 
and Sigma ortho were excluded. So the number of descriptors 
was reduced further and the component limit was set to 5. Although the Weiner Path 
and the vdw_vol descriptors show a high correlation too, the quality of the model 
decreases when one of them is left out. So they were both kept in the model. 
0.46 0.42
0.01
0.13 0.16
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Rel. Importance of Descriptors Step 4
RMSE: 0.30567 
R2:  0.93340 
XRMSE: 0.67503 
XR2:  0.70596 
Nr. C. 9 
RMSE: 0.30679 
R2:  0.93291 
XRMSE: 0.55290 
XR2:  0.78593 
Nr. C. 7 
RMSE: 0.31353 
R2:  0.92993 
XRMSE: 0.54889 
XR2:  0.79232 
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Figure 28 Descriptor correlation matrix Step 5  
 
 
Step 7: In a final step MR meta and MR para were combined additively 
to MR ges. 6 descriptors/ 5 components were used for the final 
model for this series of compounds. The additive combination of 
Pi Meta and Pi Ortho did not further improve the equation. 
 
 The QSAR equation of the model: 
log(1/EC50) = 23.801 +2.093 * Es Ortho -0.042 * vdw_vol  -0.004 * weinerPath  +1.919 * Pi 
Ortho  +0.944 * Pi Meta +2.000 * MR Ges 
 
 
RMSE: 0.32685 
R2:  0.92385 
XRMSE: 0.51934 
XR2:  0.81128 
Nr. C. 5 
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Interpretation of the model: 
The term “+2.093 * Es Ortho” indicated that big substituents in ortho position of the aromatic 
ring contributed negatively to the activity values. The Es value is the more negative the bigger 
the substituent gets. 
The term “+1.919 * Pi Ortho” showed that substituents in ortho position contribute more 
positively to the activity if they increased the lipophilicity and they contribute more negatively if 
they increased the hydrophilicity. The same was valid for substituents in the para position of 
the compound.  
Thus big and hydrophilic substituents contributed most negatively in ortho position. 
Furthermore it seems that substituents which increase the overall molar refractivity of the 
phenyl ring system also increase the activity. 
The descriptors vdw_vol and weinerPath describe size and topology of the molecules. They 
correlate with each other. Both descriptors correlated negatively with the activity. So it seemed 
that substituents at the aromatic system which enhanced the size of the compounds in a high 
degree contributed negatively to the activity as well. 
 
4.1.2 2D-QSAR model of the alkyl substituted MP 
derivatives (A2) 
 
The 25 methylphenidate derivatives of this study mainly carry 
different alkyl- or aralkyl- residues in Position R1 (Figure 29). 
These residues differ in their size and length as well as in their degree of branching and 
bulkiness. In methylphenidate there is a carboxy-methyl- ester group in this position. Some of 
the molecules also carry substituents in the para- or meta- group of the aromatic ring, mainly 
chlorine atoms. This is depicted by “R2” in Figure 29. Only in one compound the amine group is 
methylated (R3). 
Figure 29: Common Scaffold of the 
compounds analyzed in model. 
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To be able to describe the difference in size and shape of R1 groups the following two 
descriptors where chosen as a first step. The model was mainly built via forward selection of 
two additional descriptors. 
 
Step 1: The initial model based on the descriptors “weight” and 
“Zagreb”. Both of the descriptors show a high relative 
importance:  
Weight: 0.99 Zagreb: 1.00  
Step 2: To find other suited descriptors for the model an auto QSAR 
analysis was performed which made it possible to find another 
suitable descriptor for the model (PEOE_VSA-1). 
 
Step 3: As it was not possible to find another statistically beneficial 
descriptor using auto QSAR methods, other descriptors were 
checked manually. Considering the differences in size of the 
molecules a diameter descriptor was chosen for the model. 
 
Figure 30 
RMSE: 0.60831 
R2:  0.52483 
XRMSE: 0.68244 
XR2:  0.40878 
Nr. C. 2 
RMSE: 0.51547 
R2:  0.65880 
XRMSE: 0.59667 
XR2:  0.54766 
Nr. C. 3 
RMSE: 0.46143 
R2:  0.72660 
XRMSE: 0.56166 
XR2:  0.60183 
Nr. C. 4 
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Figure 31 
 
However, if one looks at the outliers it can be seen that there are two activity cliffs. The marked 
compounds in the correlation plot show these outliers (the corresponding marked structures 
can be seen in Figure 30). If the structural differences of these two compounds are considered it 
is difficult to explain the given activity values. Compound “P A2 RR/SS 10m” is a member of a 
homologues series of compounds in this dataset. If the alkyl residue is one atom longer or 
shorter the activity is more than one order of magnitude higher. In the case of compound “P A2 
RR/SS 10o” the cliff is even more drastical. Considering the small dimension of the structural 
changes and - especially in the case of compound “P A2 RR/SS 10m” the activity values of the 
homologues derivatives - the question arises, if there were errors in the measurement. 
Therefore it was also considered to exclude these two outliers. 
 
Step 4: The mentioned two outliers where excluded. 
 
 
Dat IC50 (log) = 8.477 -0.519 * diameter -0.022 * PEOE_VSA-1 +0.066 * Weight -0.130 * Zagreb 
RMSE: 0.33529 
R2:  0.85786 
XRMSE: 0.42651 
XR2:  0.77405 
Nr. C. 4 
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 Interpretation of the model: 
 
The model delivered quite a good output (RX2: 0.77) but it was not easily possible to interpret 
it. The Zagreb Index descriptor and the molecular weight descriptor correlated positively with 
each other in the given dataset while 
they showed antipodal behavior in the 
QSAR Model. The Zagreb Index is like 
the Wiener Path a topological index 
describing the shape of a molecule. 
While the molecular weight parameter 
does only consider the weight of the 
single atoms of a molecule and not 
their constellation, the Zagreb index 
also takes into account the type and number of branching of the molecule. So the descriptors 
Zagreb Index and diameter, which are both contributing negatively to the calculated activity, 
could be seen as hint that the size of the molecules is an important factor possibly because of 
space limits in the binding pocket. Maybe the weight parameter is contributing positively to the 
model because the most active compounds all carry two chlorine atoms at the meta and para 
positions of their phenyl group, which increases their molecular mass in total. This could explain 
the antipodal influences of the descriptors which describe the size of the molecules and the one 
which describes their weight. 
The PEOE_VSA-1 descriptor characterizes the size of the Van der Waals surface of atoms, which 
feature a slightly negative charge (-0.1,< qi < -0.05). (Chemical Computing Group 2009) This 
parameter contributed negatively to the activity. 
  
Figure 32 
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4.1.3  The H-QSAR Models 
 
Model for phenyl ring substituted analogues A7: 
 
All of the H-QSAR models where created following the same procedure which is described in 
detail in section “3.2.3 Creation of the H-QSAR models:”. 
 
The same compounds as in the corresponding 2D-QSAR model were used for the development 
of the model. 
 
Used Descriptors: B+Co 
 
The unique fragments were selected on basis of the types of their bonds and on the 
hybridization state of their carbon atoms. 
 
Fragment Size Best CV R2 Best Full R2  Best CV StdErr Best Full StdErr B Long Comp 
4-7 Atoms 0.912 0.973  0.418 0.230 97 6 
 
 
 
 
Figure 33 
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All the predicted activities were within one order of magnitude to the pharmacologically 
measured activity values. The H-QSAR model even performed better than the corresponding 2D 
QSAR Model. 
 
Model for alkyl substituted MP analogues (A2): 
 
The same compounds as in the corresponding 2D-QSAR model were used for the model’s 
development. 
 
Used Descriptors: A +Ch 
 
In this case unique fragments were selected on basis of their atom types as well as on their 
chirality.  
 
 
Fragment Size Best CV R2 Best Full R2 
 
Best CV StdErr Best Full StdErr B Long Comp 
4-7 Atoms 0.580 0.893 
 
0.674 0.340 59 6 
 
 
 
Figure 34 
 
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
10.0
5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5
Pred Act.
Real Act.
 4 Results 
  
 
  
Page 53 
 
  
One predicted activity calculated with the cross validated model exceeded 
the limit of one order of magnitude difference (depicted by a cross in Figure 
34). This concerned compound “P A2 RR/SS 10m” (Figure 35), which was also 
an outlier in the corresponding 2D-QSAR model. This could support the 
theory of an error in measurement concerning this compound’s activity. The 
rest of the predicted values were within the requested range. 
 
H-QSAR Model of alkyl phenyl ring substituted derivatives together (A2 +A7): 
 
Used descriptors: B + Ch +D 
Unique Fragments were selected on basis of their bond types, their chirality and their 
donor/acceptor properties. 
 
Fragment Size Best CV R2 Best Full R2 
 
Best CV StdErr Best Full StdErr B Long Comp 
5-8 Atoms 0.736 0.901   0.604 0.369 151 5 
 
 
The model’s accuracy approximately reaches an average value of the two previously created 
models which only dealt with the single studies. The residual values of four of the examined 49 
compounds exceeded the internally set mark of one order of magnitude. 
Even if the compounds of study A7 were not predicted as accurately by this HQSAR-Model as by 
the first one it could still be considered as a progress, as a prediction of more diverse 
methylphenidate derivatives is possible within one model. 
Figure 35  
“P A2 RR/SS 10m” 
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Figure 36 Correlation of the predicted (CV) versus the actual activity of the compounds (A2 + A7) 
 
 
H-QSAR Model of Study A2,A5 and the rotationally fixed MP analogues (A7) 
together: 
 
Figure 37 on the right shows the rigid scaffold of the compounds of study A5. 
The authors wanted to bring to light what role methylphenidate’s free 
rotatetability plays for the binding affinity. 
 
Used descriptors: B+Co+D 
Unique fragments were selected on basis of their bond types, the hybridization state of their 
carbon atoms and based on their donor/acceptor properties. 
 
Fragment 
Size Best CV R2 Best Full R2 
 
Best CV 
StdErr 
Best Full 
StdErr B Long Comp 
4-7 Atoms 0.650 0.854   0.673 0.435 53 6 
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Figure 37  
Rigidized Compounds 
Study A5 
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The lower correlation of the predicted versus the actual activity values can also be observed in 
the correlation graph (Figure 38.) The residual values of nine of the observed 66 compounds 
(13.6%) exceeded the internally set mark of one order of magnitude.  
This model again points out the difficulty of finding a good QSAR model for a rather diverse 
subset of structures. The predicted activity values of three compounds of each of the three 
studies exceeded that limit respectively. 
 
Figure 38 
 
When the H-QSAR models were analyzed visually, it was not possible in all models to draw 
conclusions concerning the contributions of single fragments via the standard color encoded 
interpretation tool which is included in the Sybyl Software package. 
Normally this tool depicts fragments which contribute negatively or positively to the calculated 
activity values in different color patterns. This would have made it possible to better 
understand the properties of the analyzed compounds. 
Nevertheless, predictive HQSAR models could be created, which could also be used to 
strengthen results which were obtained by the use of the previously developed 2D-QSAR 
Models. 
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4.1.4 Résumé for the Ligand based analyses of methylphenidate derivatives: 
 
The QSAR experiments gave an insight into the properties of the methylphenidate analogues 
and on influences on the activity of structural modification of the compounds. The set of 
available synthesized derivatives of this rather small compound is extremely rich. A wide variety 
of modifications was done and examined for nearly every position of the structure. It seems no 
element of the structure is irreplaceable. High potent and selective derivatives can be found in 
every class of the modified compounds. 
That is also why it was decided to examine the influence of structural modifications in a smaller 
breadth. 
These insights especially on phenyl substituted analogues could be used for the interpretation 
of the docking experiments. The combination of ligand und structure based methods is realized 
in the section (5 Discussion). 
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4.2 Docking  
 
4.2.1 Docking with GOLD 
 
The detailed workflow of the final docking run is described at the beginning of the “Methods” 
section. 
The analysis of the final docking run produced the following results: 
150 poses were calculated for each of the six ligands (Figure 39). So the run produced 900 
poses in total. The scaffold clustering of these 
poses with a threshold of 2.0 Å resulted in 17 
clusters. Two of these clusters (Cluster 9 and 12) 
contained poses of all six compounds.  
However, when the clusters where checked in 
detail it was found that there were two different 
positionings of methylphenidate within one 
cluster. 
Thus, the RMSD range of each cluster had to be 
decreased. Different thresholds were investigated 
(1.5Å, 1.6Å, 1.7Å). On the one hand the deviation 
should not be too low (otherwise no cluster was retrieved which contained all compounds) and 
on the other hand not too high. 
Considering these criteria 1.6Å was found as the optimal value. Only one cluster 
remained containing all compounds. The remaining cluster carries the label Cluster 25 and 
contains 158 poses. The omitted cluster (Cluster 21) lacks poses of methylphenidate itself and 
only contains one pose of the di-chloro substituted analogue. In total it contains 163 poses. 
Figure 39 
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Nevertheless, Cluster 21 was also analyzed here as it was also present in the MOE docking 
experiment where it contained poses of all derivatives. 
 
Cluster 25: 
 
In this positioning the phenyl ring of all compounds is pointing towards solvent direction.  As is 
observed in each cluster the ionic interaction between ASP79 and the Nitrogen group in the 
ligands is the most dominant one and occurs in the majority of the poses. Furthermore, Phe320 
interacts with the amine group, 
partly via its backbone’s carbonyl 
group, partly via its -rich in 
electrons- aromatic side chain.  
Interactions with Tyr156 can be 
observed most often within poses 
of the two ester compounds. 
Either aromatic stacking 
interactions between the two 
aromatic rings of methyl-
phenidate and Tyr156 (as it can 
also be seen in Figure 40) or a 
hydrogen bond between the 
Tyr156’s hydroxyl group and the 
carbonyl oxygen of 
Methylphenidate/ Di-Cl- Methyl-
phenidate can be observed. 
Interactions with the residues Tyr156 and Asp79 are especially interesting as they are also 
known to be important for cocaine binding to the Dopamine transporter (Beuming et al. 2008). 
Though the mode of interaction for methylphenidate is not known in detail, its effects on the 
Dopamine uptake and respectively the Dopamine transporter are very similar to those of 
Figure 40 
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cocaine (see 1.1.3 Important interacting Drugs). Thus it is likely that Tyr156 is of importance for 
the binding of methylphenidate too. 
Unfortunately, interactions with an aromatic π-electron system cannot be depicted or included 
in the statistical analyses of a PLIF in MOE. These interactions can only be observed when one 
looks at each complex and its interactions manually. The interaction rate with Tyr156, Phe320 
and Phe326, shown in Figure 41, would be much higher if also π-π interactions would be 
considered by the MOE’s PLIF algorithm. That is also why the interactions with Phe326, which 
can be seen in Figure 40, do not show up at all in the PLIF. An interaction which could only be 
observed with the ester analogues is the hydrogen bond between the hydroxyl group of Ser422 
and the carbonyl group. 
 
 
Figure 41 PLIF Cluster 25 
 
Composition of Cluster 25:    Composition of Cluster 21: 
P A1 3,4CTMP 103 Poses  P A1 3,4CTMP 1 
P A2 RR 10c 4 Poses  P A2 RR 10c 2 
P A2 RR 10j 8 Poses  P A2 RR 10j 51 
P A2 RR 10k 15 Poses  P A2 RR 10k 50 
P A2 RR 10h 6 Poses  P A2 RR 10h 59 
TMP 22 Poses  TMP 0 
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The Clusters were also compared with 
respect to their GOLD Score Values. To 
achieve this, the two clusters were 
merged to one database. Then the 
poses of both clusters were ranked 
according to their Gold score values. 
Cluster 25 is definitely preferred 
according to these values. The top 
scored 127 poses -of 321 in total- all 
belong to cluster 25. This represents 
more than 80% of the poses of this 
cluster. 
 
Cluster 21: 
In this cluster the alkyl- or ester- side 
chain is pointing towards a solvent 
exposed area while the aromatic ring is 
pointing to the inside of the 
transporter, facing TMD 3. Figure 42 
shows Cluster 21 in comparison to 
Cluster 25. It is visible that the ester and 
the aromatic group swapped their 
position. Hardly any π-π interactions with Tyr156 are possible in this cluster as the compound’s 
aromatic system is too far away from Tyr156’s side chain and also fewer interactions between 
Phe320’s π system and methylphenidate’s charged nitrogen occur.  
Figure 42 
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4.2.2 Docking with MOE 
 
In this docking run the same pocket in the rigid protein was used in combination with the same 
6 ligands used in the GOLD docking run. The “Triangle Matcher” was used as a placement 
method and the “London dG” scoring function for rescoring purposes. 
After the automatic elimination of duplicate poses approximately 60 poses per ligand were 
retrieved. The complexes were minimized using MOE’s LigX tool. Afterwards the poses were 
clustered with a threshold of 3 Å according to the RMSD of the ligands, using the same SVL 
Clustering script (within MOE) which was described in Section “3.3.5.5  Final Workflow: Docking 
with flexible sidechains in GOLD”. 
All clusters which did not contain poses of all of the six ligands where omitted. This brought up 
three final clusters, Cluster 16, Cluster 29 and Cluster 37.  
Two of the three clusters resemble with the two Gold clusters, MOE Cluster 37 with GOLD 
Cluster 25 and MOE Cluster 29 with GOLD Cluster 21.  
The positioning of the third one Cluster 16 is a new one, depicted in Figure 43. 
 
Figure 43: In Cluster 16 the carboxy-methyl-ester and the phenyl ring are oriented towards the outside of the pocket. The 
aromatic ring is closer to Tyr156’s sidechain. This allows interactions with this residue in some of the cluster’s 
poses. 
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Different approaches were tried to rank the clusters. 
 First, the results were rescored using four 
different scoring functions: ASE, Alpha HB, 
Affinity dG and London dG. The proportion 
of each pose under the 15 top scored poses 
calculated with the different scoring 
methods was determined. The mean over 
all of the different methods was taken as a 
criterion.  The result can be seen in Figure 
44. Cluster 29 was curtly ranked best. Nevertheless,  the difference between the clusters 
is rather small especially if the large deviation between the scoring functions is 
considered. Cluster 29 shows highest and Cluster 37 the lowest standard deviation 
between the scoring functions. 
 
 As a second criterion the assumption was 
made that the amino acid residues Tyr156 
and Asp79 are important for the 
methylphenidate binding, based on the 
experimental cocaine data which was 
already explained in section “4.2.1
 Docking with GOLD”. While in all 
clusters nearly in 100% of the poses there is 
an interaction between Asp 79 and the amine group of the methylphenidate analogues, 
the interaction rate with Tyr156 varies. Figure 45 depicts the interaction rate in the 
three clusters in percent. π-π- aromatic stacking interactions of Tyr156 with the 
methylphenidate’s phenyl group are considered. In cluster 16 you also see hydrogen 
Figure 44 
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bond interactions between Tyr156 phenolic hydroxyl group and the carbonyl group of 
the ester compounds (TMP, P A1 3,4CTMP). 
Cluster 37 is the only cluster in which there is at least one pose showing interactions 
with Tyr156 as well as Asp79 at the same time. 
 
 Also the size of the clusters was considered. 
Figure 46 shows the number of poses within 
each cluster. 
Cluster 37 was the biggest one. 
 
 
 As already mentioned only two of the clusters 
were also obtained in the GOLD docking experiments. That was taken as a final criterion. 
 
 
Taken these criterions (especially the size and the interaction pattern) into account and also 
considering the results of the GOLD docking run, Cluster 37 (shown in Figure 47 next page) was 
chosen as the preferred one and the other two were omitted. 
 
4.2.3 Comparison of MOE and GOLD Results 
 
When the PLIFs of the final clusters are compared (see page 65, Figure 48) one can see quite a 
similar interaction pattern which is obvious as the positionings within the two clusters concur 
closely. However, the interaction rate with each residue is not equal throughout the clusters, 
which can be explained when one keeps in mind that in the GOLD run side chains were kept 
flexible while in the MOE run it was docked into a rigid protein. There are more contact 
interactions with the amino acids Ser149, Val152, Ser422 and Gly426 in the MOE Cluster. The 
lack of sidechain flexibility could be an explanation for that. Furthermore, some intereactions  
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(with similar partner-residues in the protein) differ in their nature: In the final GOLD cluster 
mainly the ester compounds interact with Ser422 via a hydrogen bond to its hydroxyl group, in 
the MOE Cluster preferentially the lipophilic alkyl analogues interact with this residue via 
contact interactions. That is mainly the case because Ser422 hydroxyl group is pointing out of 
the pocket in the rigid model while it is pointing towards the molecule in some poses in the 
flexible run. Neither the PLIF of the MOE Cluster nor the one describing the GOLD cluster show 
any π-ion interactions of Phe326 and the amine nor the π-π- Interactions between Tyr156 and 
Methylphenidate’s Phenyl ring although they occur in both analyses. 
Figure 47: Comparison of the final clusters. 
 For a better overview a 2D interaction map of the poses is shown at the bottom.  
 The Atoms marked in purple show areas with exposure to the solvent 
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Also only the Backbone – Ion Interactions between Phe320 and the amine are considered in the 
PLIF, not the π-Ion interactions. 
The problem that the PLIF does not show interactions involving π electron systems was already 
mentioned in “4.2.1 Docking with GOLD”. In Figure 47 comparative poses from both clusters 
and also the interactions involving π electron systems are depicted. 
  
Figure 48 
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5 Discussion 
 
 
The docking run was based on the proposed cocaine binding pose of (Beuming et al. 2008). This 
proposed binding pocket which, as already mentioned, overlaps with that of dopamine, was 
extensively validated by mutational and cross linking experiments (Beuming et al. 2008). Even if 
the pharmacological mechanism of methylphenidate and cocaine is similar - they are both 
blocking the dopamine transporter - one cannot be sure if they do so by binding in an 
analogous manner. It is risky to make assumptions for the binding mode of one compound 
based on experimental data of another, related agent. However, as there is no mutational 
analysis data available for methylphenidate itself, this was taken as a basis.  
The same is true for assumptions for single interaction partners (for example in this work: 
Asp79). 
 
Proposed Interactions for methylphenidate and its analogues: 
 
Asp79 is a strong interaction partner for methylphenidate as it forms an ionic bond with the 
compound’s protonated amine. This positive charge within methylphenidate is also the 
interaction partner for the residues Phe320 and Phe326. 
The interactions with Tyr156 are present throughout all the docked compounds, either via a π-
π- Interaction or via a hydrogen bond, formed between the hydroxyl group and the carbonyl 
group of methylphenidate (the latter is only concerning the ester analogues and 
methylphenidate). Furthermore, this carbonyl group is a possible hydrogen bond acceptor for 
Ser422.  
It is questionable if the contact interactions between the compounds and the protein (Ser149, 
Val 152, Val328, Ser422 and Gly426) are very important for the methylphenidate’s binding 
mode, as these, on the one hand, are very weak interactions and on the other hand do occur in 
the rigid docking run in a much higher degree. This may point out the importance of flexibility in 
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a docking process as this interaction could not be observed within the flexible docking runs. It 
was published recently in “Current Opinion in Structural Biology” that 50%-70% of the 
calculated binding poses based on rigid proteins models, only considering one conformation of 
the receptor, are incorrect. (Totrov and Abagyan 2008) 
To circumvent those problems the flexible side chain workflow used in the GOLD docking run 
was developed. 
So even if the results of both docking runs are closely related and one strengthens the other the 
flexible one may be preferred when it comes to details especially considering weak interactions. 
 
Correlation of activity values of methylphenidate derivatives and insights obtained in QSAR 
analysis with the proposed docking pose: 
 
The Amine: This model shows the importance of the ionic interaction with Asp79, which is also 
a proposed key interaction for cocaine binding. Nevertheless, also Oxa- and Carba-cyclic 
methylphenidate analogues show inhibitory potential. When the nitrogen atom is changed to 
oxygen the affinity decreases by nearly 3 orders of magnitude. If the aromatic ring is 
additionally substituted with two chlorine atoms in meta and para position the affinity stays 
within one order of magnitude of the corresponding nitrogen analogue (Meltzer et al. 2003). 
These chlorine substituents are likely to have high influence on the interaction strength of the 
compounds. As it was published by Froimowitz (Froimowitz et al. 2007) even the otherwise 
inactive erythro diastereomers of alkylated methylphenidate analogues show high interaction 
potential when the aromatic ring is 3,4- Di-chloro substituted. 
The phenyl group and its substitution: Figure 49 on the next page shows the protein surface of 
the pocket. Green color indicates lipophilic surface area whereas the violet one shows 
hydrophilic area. As it can be seen the methylphenidate’s aromatic system is surrounded by a 
lipophilic surface area. This is on the one hand plausible by itself - the phenyl group is a 
lipophilic structure - and on the other hand could be an explanation why halogen substituents  
in meta and para increase the affinity (Deutsch et al. 1996) as they increase the lipophilicity. 
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Furthermore, the observed π – stacking interaction with Tyr156 could be an explanation for the 
increased activity of the halogen substituted compounds, as the aromatic system is enriched in 
electrons by halogen atoms via mesomeric effects. The 2D 
QSAR model dealing with the influence of different 
substituents at the phenyl group (4.1.1  2D-QSAR 
Model phenyl ring substituted analogues (A7)) approved 
the positive influence of substituents which increase the 
lipophilicity in para position as well as in ortho position. 
However, it also shows that the positive effect of increased 
lipophilicity of these substituents does not play a role as 
the hindering effect of the size of these substituents 
prevails. The docking model cannot explain the nature of 
this sterical hindrance although the pocket is quite narrow in this region and a slight expansion 
of the pocket might be necessary to accommodate these ligands. 
 
Outlook 
 
Docking poses always represent only snapshots of interactions with a receptor or target 
protein. Even if side chains are kept flexible during the docking run this is a rather small degree 
of flexibility as the interaction process is a dynamic one. 
To meet these requirements better it would make sense to dock into different receptor 
conformations, which is already known to improve docking results (Totrov and Abagyan 2008). 
This would be a possibility to consider a broader degree of flexibility as well as different 
interaction patterns of ligand and protein at different stages of the interactions. 
Furthermore molecular dynamic simulations could be a second step to a better understanding 
of the ligand’s behavior in the binding pocket and its environment. 
Finally mutational analysis of the proposed interacting amino acid residues would be important 
for the validation of the model. Asp79, Tyr156, Phe320, Phe326 also Ser422 are the most 
Figure 49 Pocket Surface 
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interesting candidates for these mutational studies. If methylphenidate’s affinity decreases with 
the exchange of these amino acids this would strengthen the proposed binding mode. 
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B Abstract 
 
The Dopamine Transporter which terminates a dopaminergic neuronal signal by withdrawing 
the monoamine neurotransmitter Dopamine from the synaptic cleft is the target of many 
psychoactive compounds. Methylphenidate blocks this transporter very selectively in respect to 
other monoamine transporters. While Methylphenidate’s pharmacological effects are well 
studied and it is also used widely in therapy the molecular basis of its interaction is still 
uncovered. 
In this study QSAR analyses using different sets of 2D descriptors as well as Hologram-QSAR 
analyses were performed in the MOE and SYBYL Software packages to point out the influence 
of different structural modifications of methylphenidate derivatives on their activity. The 
gained information was also used for interpretational purposes in combination with docking 
experiments. For the docking experiments a workflow was created, composed of the docking 
process with flexible side chains in the GOLD Suite, a step of minimization of the complexes, 
RMSD clustering of the received poses and the evaluation in the MOE Software package. A 
homology model based on the bacterial Leucine transporter had to be used, since currently no 
X-Ray structure of the Dopamine transporter is available. Six different ligands, methylphenidate 
and 5 derivatives, all with relatively high affinity (3.6- 130nM), were docked. A common binding 
mode for all six docked ligands could be found in Dopamine’s binding pocket. 
To validate the positioning it was checked if the activity of active and inactive methylphenidate 
derivatives can be explained with the proposed interactions in the pocket. Furthermore it was 
checked if observations from the QSAR experiments could be explained by the docking model. 
Although there are still open questions concerning the activity of some analogues, which have 
to be investigated in further experiments, many trends observed in QSAR–Analyses were 
explained in the docking pose. The proposed binding mode shows interactions with the amino 
acids Asp79, Tyr156, Phe320, Phe326 and Ser422. These residues are proposed for following 
mutagenesis studies.  
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C Zusammenfassung 
 
Der Dopamintransporter, welcher dopaminerge neuronale Signale durch die Wiederaufnahme 
des Neurotransmitters Dopamin aus dem synaptischen Spalt in das Neuron beendet, ist das Ziel 
vieler psychoaktiver Verbindungen. Methylphenidat blockiert diesen Transporter sehr selektiv 
im Bezug auf andere Monoamin-Transporter. Während Methylphenidats pharmakologische 
Wirkung gut untersucht und es auch in der Therapie weit verbreitet ist, bleibt sein genauer 
Interaktionsmodus immer noch ungeklärt. 
In dieser Arbeit wurden QSAR Analysen unter der Verwendung von 2D Deskriptoren sowie 
Hologramm-QSAR Analysen mithilfe der Softwarepakete „MOE“ und „Sybyl“ durchgeführt, um 
die strukturellen Einflüsse verschiedener Methylphenidat Derivatisierungen auf die Aktivität zu 
untersuchen. Die gewonnen Erkenntnisse wurden anschließend zur Interpretation von Docking 
Experimente verwendet. Für die Docking Experimente wurde ein Workflow erstellt der das 
Docken mit flexiblen Seitenketten in der GOLD Suite, einem Komplex-Minimierungsschritt, 
RMSD Clustering der erhaltenen Posen und die Auswertung im MOE Softwarepaket umfasst. Es 
wurde ein Homologiemodell auf Basis des bakteriellen Leucin Transporters verwendet, da 
zurzeit keine Röntgenstruktur des DAT verfügbar ist. Methylphenidat und fünf Derivate mit 
relativ hoher Aktivität (3.6-130nM) wurden gedockt. Dabei konnte ein gemeinsamer 
Bindungsmodus für alle sechs Liganden gefunden werden. 
Um diese Positionierung zu validieren wurde überprüft ob die Affinitätswerte aktiver sowie 
inaktiver Derivate durch Interaktionen und Hindernisse im vorgeschlagenen Modell erklärbar 
sind. Außerdem wurde überprüft ob Erkenntnisse aus den QSAR Analysen im Docking Model 
wiedergefunden werden können. Obwohl immer noch Fragen die die Aktivität einiger Derivate 
betreffen offen sind, die in weiteren Experimenten geklärt werden müssen, konnten viele 
Trends der QSAR-Analysen über die Docking Posen erklärt werden. Der Vorgeschlagene 
Bindungsmodus zeigt Interaktionen mit Asp79, Tyr156, Phe320, Phe326 und Ser422, welche als 
Ziel für nachfolgende Mutationsexperimente vorgeschlagen werden. 
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D Abbreviations: 
 
 
BB  (Protein) Back Bone 
DAT  The Dopamine Transporter 
MOE  Molecular Operating Environment 
NET  The Noradrenalin Transporter 
Nr. C.  Number of Compounds used in a QSAR Model 
PLIF  Protein Ligand Interaction Fingerprint 
RMSD  Root Mean Square Distance 
RMSE  Root Mean Square Error 
R2   Correlation Coefficient 
SERT  The Serotonin Transporter  
SLD  Small Ligand Docking 
TMD  Transmembrane domain 
XRMSE  Cross-validated Root Mean Square Error 
XR2  Cross-validated Correlation Coefficient 
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E Molecular Descriptors: 
 
Descriptor Properties Rescource 
diameter “Largest vertex eccentricity in graph” 
(Chemical Computing 
Group 2009) 
Es 
Taft Size parameter  The bigger the residue the 
more negative is his Es Constant 
(Hansch 1979),(Todeschini 
and Consonni 2000) 
MR 
The molar refractivity is calculated considering 
the weight, the polarizability and the refractivity 
index. The descriptor shows the contribution of 
aromatic substituent‘s to the compounds MR.  
(Hansch 1979),(Todeschini 
and Consonni 2000) 
Pi 
Aromatic substituent‘s hydrophobicity constant: 
Residues which increase lipophilicity have 
positive values, Residues which decrease it have 
negative values 
(Hansch 1979) 
PEOE_VSA-1 
Total VDW surface area of a group of atoms with 
a certain partial charge  (-0.1, -0.05) 
(Yang et al. 2007) 
vdw_vol  Van der Waals Volume 
(Chemical Computing 
Group 2009) 
weinerPath  
A topological index descriptor. Calculated on 
bases of the topological distances within the 
chemical graph of the structure.  
(Chemical Computing 
Group 2009), (Todeschini 
and Consonni 2000) 
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Weight  molecular weight 
(Chemical Computing 
Group 2009) 
Zagreb  
The Zagreb index belongs to the group of 
topological indices. It describes a molecules 
topology and it is calculated based on the sum of 
squared vertex valences of the molecular graph 
of the molecule. 
(Bonchev 1983; 
Todeschini and Consonni 
2000; Chemical 
Computing Group 2009) 
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G Compounds used for the QSAR Models 
 
Detailed structures: Section  (H Methylphenidate derivative Database) 
 
Model 1 (P A7):  The compounds mainly differ in the substitution of the phenyl ring. 
P A7 1aa, P A7 1b, P A7 1d, P A7 1e, P A7 1f, P A7 1g, P A7 1i, P A7 1j, P A7 1k, P A7 1l, P A7 1m, 
P A7 1n, P A7 1o, P A7 1p, P A7 1q, P A7 1r, P A7 1s RAC SS, P A7 1t P A7 1u, P A7 1v, P A7 1w, P 
A7 1x, P A7 1y, P A7 1z. 
 
Model 2 (P A2): The compounds mainly differ in the alkyl substitution which replace the 
carboxy-methyl-ester group of methylphenidate: 
 
P A2 RR/SS 10a, P A2 RR/SS 10b, P A2 RR/SS 10c, P A2 RR/SS 10d, P A2 RR/SS 10e, P A2 
RR/SS10f, P A2 RR/SS 10g, P A2 RR/SS 10h, P A2 RR/SS 10i, P A2 RR/SS 10j, P A2 RR/SS 10k, P A2 
RR/SS 10l, P A2 RR/SS 10m, P A2 RR/SS 10n, P A2 RR/SS 10o, P A2 RR/SS 10p, P A2 RR/SS 10q, P 
A2 RR/SS 10r, P A2 RR/SS 10s, P A2 RR/SS 10t, P A2 RR/SS 11, P A2 RR/SS 11u, P A2 RR/SS 10v, P 
A2 RR/SS 10w, P A2 RR/SS 15 
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